JRROBYN,
Talk to those in charge of “the process” that keeps a safe treatment from patients for more than a decade to protect the status quo. Big money greases lots of skids to keep the money coming. NWBO represents a change to that way of doing business as usual as they did all the leg work to bring this forward into a viable business model that can be replicated without big pharma taking it from them or their investors beforehand.
With all solid tumors, both resectable and un resectable being targeted and proteomics identifying viral and bacterial targets as well by this platform, the future seems limited only by the time it takes to build the infrastructure needed to treat all those who will be asking for it with NWBO currently the one to determine who is in and who is out. The status quo really isn’t too excited about that prospect. Best wishes.
News 
Market Data 
Discover 
